Blueberries Medical Secures C$1 Million in Private Funding Round
Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) has taken an important step in its growth journey by announcing a non-brokered private placement, through which they plan to sell approximately 96 million common shares at C$0.011 each, raising an impressive total of around C$1.05 million. This funding will be instrumental in expanding their operations and enhancing their corporate capabilities.
Purpose of the Private Placement
The proceeds from this private placement are designated mainly for operational expansion and general working capital. This strategic move is aimed at strengthening Blueberries Medical's position in the burgeoning medicinal cannabis industry, particularly in Latin America.
Leadership and Participation
Notably, this offering is expected to be led by Terraflos Inc., a well-regarded cannabis enterprise with extensive operations across Latin America. The involvement of Terraflos, particularly its chairman and CEO, Facundo Garreton, and director, Guillermo Rodriguez, signals a strong commitment to the company's future.
Understanding Related Party Transactions
The participation of insiders, including both Garreton and Rodriguez, qualifies as a related party transaction under Canadian securities regulations. Blueberries Medical will rely on specific exemptions to expedite the financing process. They are confident that their proactive approach will allow for quick access to critical funding.
About Blueberries Medical Corp.
Operating mainly from the Bogotá Savannah in Colombia, Blueberries Medical Corp. has established itself as a licensed producer of high-quality cannabis derivatives. Their expertise spans across agriculture, genetics, and pharmacology, positioning the company as a leading distributor of CBD and THC-based products. They are dedicated to the cultivation, production, and export of medical cannabis, adhering to rigorous international standards.
Scientifically-Driven Approach
With a team of specialists in various fields including pharmacology and marketing, Blueberries leverages cutting-edge techniques to create naturally grown cannabis extracts. Their commitment to quality places them ahead in the competitive landscape of international cannabis production.
Future Outlook for Blueberries Medical
In addition to expanding their operations in Colombia, Blueberries Medical has ambitions to penetrate broader Latin American and international markets. Their planned developments in cultivation and extraction processes aim to meet the increasing global demand for medicinal cannabis.
Challenges and Market Conditions
Blueberries Medical is cognizant of the fluctuating conditions within the macroeconomic landscape and cannabis market. They actively monitor these dynamics to adapt their strategies accordingly.
Frequently Asked Questions
What is the purpose of the private placement announcement?
The private placement aims to raise funds to expedite the expansion of Blueberries Medical’s operations and support working capital needs.
Who will lead the private placement?
The private placement will be led by Terraflos Inc., a seasoned cannabis company operating in Latin America.
Are the insiders participating in the offering?
Yes, insiders including Facundo Garreton and Guillermo Rodriguez will participate, qualifying this as a related party transaction.
Where does Blueberries Medical operate?
Blueberries Medical primarily operates from the Bogotá Savannah in Colombia, focusing on the production of cannabis derivatives.
What future plans does Blueberries Medical have?
The company intends to enhance its cultivation and extraction processes to meet growing demands in both local and international markets.
